[SCHEDULE 14A INFORMATION Check the appropriate box: [ ] Preliminary Proxy Statement [ ] [ ] Definitive Proxy Statement [X] Definitive Additional Materials [ ] Soliciting Material under Rule 14a-12 CHINA BIOLOGIC PRODUCTS, INC. __________________________________________________________ Payment of Filing Fee (Check the appropriate box): [ ] No fee required [ ] Fee computed on table below per Exchange Act Rules 14a-6(i)(1)]
[SCHEDULE 14A INFORMATION Check the appropriate box: [ ] Preliminary Proxy Statement [ ] [ ] Definitive Proxy Statement [X] Definitive Additional Materials [ ] Soliciting Material under Rule 14a-12 CHINA BIOLOGIC PRODUCTS, INC. __________________________________________________________ Payment of Filing Fee (Check the appropriate box): [ ] No fee required [ ] Fee computed on table below per Exchange Act Rules 14a-6(i)(1)]
[SCHEDULE 14A INFORMATION Check the appropriate box: [ ] Preliminary Proxy Statement [ ] [X] Definitive Proxy Statement [ ] Definitive Additional Materials [ ] Soliciting Material under Rule 14a-12 CHINA BIOLOGIC PRODUCTS, INC. __________________________________________________________ Payment of Filing Fee (Check the appropriate box): [ ] No fee required [ ] Fee computed on table below per Exchange Act Rules 14a-6(i)(1)]
[SCHEDULE 14A INFORMATION Check the appropriate box: [ ] Preliminary Proxy Statement [ ] [X] Definitive Proxy Statement [ ] Definitive Additional Materials [ ] Soliciting Material under Rule 14a-12 CHINA BIOLOGIC PRODUCTS, INC. __________________________________________________________ Payment of Filing Fee (Check the appropriate box): [ ] No fee required [ ] Fee computed on table below per Exchange Act Rules 14a-6(i)(1)]
[Company Contact Mar. 31, 2011 (PR Newswire) -- China Biologic Products Reports Record Sales and Net Income for 2010 Tai'an, Shandong Province, PRC, March 31, 2010 – China Biologic Products, Inc. (NASDAQ: CBPO) (“China Biologic” or the “Company”), one of the leading plasma-based biopharmaceutical companies in the People’s Republic of China (“PRC”), today reported record sales and net income for] [FORM 8-K CURRENT REPORT Date of Report (Date of Earliest event Reported): April 1, 2011 ( March 31, 2011) CHINA BIOLOGIC PRODUCTS, INC. Delaware 001-34566 75-2308816 (State or other jurisdiction of (Commission File No.) (IRS Employer ID No.) incorporation or organization) No. 14 East Hushan Road, Tai'an City, Shandong, 271000 People's Republic of China 86-538 -620-2306 ____________________________________________________________ (Former name or]
[Company Contact Mar. 31, 2011 (PR Newswire) -- China Biologic Products Reports Record Sales and Net Income for 2010 Tai'an, Shandong Province, PRC, March 31, 2010 – China Biologic Products, Inc. (NASDAQ: CBPO) (“China Biologic” or the “Company”), one of the leading plasma-based biopharmaceutical companies in the People’s Republic of China (“PRC”), today reported record sales and net income for] [FORM 8-K CURRENT REPORT Date of Report (Date of Earliest event Reported): April 1, 2011 ( March 31, 2011) CHINA BIOLOGIC PRODUCTS, INC. Delaware 001-34566 75-2308816 (State or other jurisdiction of (Commission File No.) (IRS Employer ID No.) incorporation or organization) No. 14 East Hushan Road, Tai'an City, Shandong, 271000 People's Republic of China 86-538 -620-2306 ____________________________________________________________ (Former name or]
[FORM 10-K/A (Amendment No. 2) (Mark One) [X] December 31, 2009 Commission File No. 001-34566 CHINA BIOLOGIC PRODUCTS, INC. DELAWARE 75-2308816 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) No. 14 East Hushan Road, (+86) 538-620-2306 Title of each class Name of each exchange on which registered Common Stock, Par Value $0.0001 The NASDAQ Stock Market] [CERTIFICATIONS I, Chao Ming Zhao, certify that: 1. I have reviewed this annual report on Form 10-K of China Biologic Products, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such] [CERTIFICATIONS I, Y. Tristan Kuo, certify that: 1. I have reviewed this annual report on Form 10-K of China Biologic Products, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such] [2. Information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company. Chao Ming Zhao Chief Executive Officer] [OF THE SARBANES-OXLEY ACT OF 2002 2. Information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company. Y. Tristan Kuo Chief Financial Officer (Principal Financial and Accounting Officer)]
[FORM 10-K/A (Amendment No. 2) (Mark One) [X] December 31, 2009 Commission File No. 001-34566 CHINA BIOLOGIC PRODUCTS, INC. DELAWARE 75-2308816 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) No. 14 East Hushan Road, (+86) 538-620-2306 Title of each class Name of each exchange on which registered Common Stock, Par Value $0.0001 The NASDAQ Stock Market] [CERTIFICATIONS I, Chao Ming Zhao, certify that: 1. I have reviewed this annual report on Form 10-K of China Biologic Products, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such] [CERTIFICATIONS I, Y. Tristan Kuo, certify that: 1. I have reviewed this annual report on Form 10-K of China Biologic Products, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such] [2. Information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company. Chao Ming Zhao Chief Executive Officer] [OF THE SARBANES-OXLEY ACT OF 2002 2. Information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company. Y. Tristan Kuo Chief Financial Officer (Principal Financial and Accounting Officer)]
[FORM 8-K CURRENT REPORT Date of Report (Date of Earliest event Reported): March 31, 2011 ( March 30, 2011) CHINA BIOLOGIC PRODUCTS, INC. Delaware 001-34566 75-2308816 (State or other jurisdiction of (Commission File No.) (IRS Employer ID No.) incorporation or organization) No. 14 East Hushan Road, Tai'an City, Shandong, 271000 People's Republic of China 86-538 -620-2306 ____________________________________________________________ (Former name or]
[FORM 8-K CURRENT REPORT Date of Report (Date of Earliest event Reported): March 31, 2011 ( March 30, 2011) CHINA BIOLOGIC PRODUCTS, INC. Delaware 001-34566 75-2308816 (State or other jurisdiction of (Commission File No.) (IRS Employer ID No.) incorporation or organization) No. 14 East Hushan Road, Tai'an City, Shandong, 271000 People's Republic of China 86-538 -620-2306 ____________________________________________________________ (Former name or]
